Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRTH: T-DM1 and Whole-brain Radiotherapy in HER2-positive Breast Cancer Brain Metastases
NCT02135159Phase 1Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Feb 2014
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab emtansine in breast cancer (4 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Optimal sequences of combined treatment at 3 months. Started Feb 2014; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02135159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135159.